Featured
-
-
Clinical Study
| Open AccessPhase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
- Yvette Drew
- , Jonathan Ledermann
- & Ruth Plummer
-
Translational Therapeutics
| Open AccessOptimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours
- Sonya C Tate
- , Teresa F Burke
- & Damien M Cronier
-
Epidemiology
| Open AccessAnalgesic medication use and risk of epithelial ovarian cancer in African American women
- Lauren C Peres
- , Fabian Camacho
- & Joellen M Schildkraut
-
Short Communication
| Open AccessChetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma
- Elena Viziteu
- , Camille Grandmougin
- & Jerome Moreaux
-
Clinical Study
| Open AccessPhase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies
- K Yong
- , J Cavet
- & J Cavenagh
-
Mini Review |
PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions
- Jonathan A Ledermann
- & Fatima El-Khouly
-
Clinical Study
| Open AccessA phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma
- Jeong-Hoon Lee
- , Yoon Lee
- & Yoon Jun Kim
-
Clinical Study
| Open AccessPredictive role of hand–foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer
- Christoph Zielinski
- , Istvan Lang
- & Thomas Brodowicz
-
Short Communication
| Open AccessNovel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer
- Alessio Amatu
- , Alessio Somaschini
- & Salvatore Siena
-
Translational Therapeutics
| Open AccessIncreased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin
- B Colmegna
- , S Uboldi
- & M D'Incalci
-
Clinical Study
| Open AccessA phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium
- S Lheureux
- , A M Oza
- & R Goel
-
Clinical Study
| Open AccessPhase I study of afatinib combined with nintedanib in patients with advanced solid tumours
- Rastislav Bahleda
- , Antoine Hollebecque
- & Jean-Charles Soria
-
Clinical Study
| Open AccessA randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer
- S H Lim
- , T W Kim
- & W K Kang
-
Clinical Study
| Open AccessA randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results
- T Eisen
- , A-B Loembé
- & I Bondarenko
-
Clinical Study
| Open AccessNab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
- Alix Portal
- , Simon Pernot
- & Julien Taieb
-
Letter to the Editor
| Open AccessComment on ‘Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma’
- Susannah Ellsworth
- & Stuart A Grossman
-
Letter to the Editor
| Open AccessResponse to: Comment on ‘Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma’
- Eric T Wong
- & Kenneth D Swanson
-
Clinical Study
| Open AccessLong-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer
- Ruud van der Noll
- , Serena Marchetti
- & Jan H M Schellens
-
Clinical Study
| Open AccessAre metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another?
- M M J Zanders
- , M P P van Herk-Sukel
- & L V van de Poll-Franse
-
Clinical Study
| Open AccessClinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer
- Nathalie Quenel-Tueux
- , Marc Debled
- & Richard Iggo
-
Clinical Study
| Open AccessA phase II and pharmacodynamic study of sunitinib in relapsed/refractory oesophageal and gastro-oesophageal cancers
- C Wu
- , S Mikhail
- & T Bekaii-Saab
-
Short Communication
| Open AccessImpact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer
- P A Jänne
- , I Smith
- & P Smith
-
Clinical Study
| Open AccessFinal results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma
- M E Gore
- , C Szczylik
- & R Bukowski
-
Clinical Study
| Open AccessPhase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer
- T Macarulla
- , A Cervantes
- & F Ciardiello
-
Clinical Study
| Open AccessRandomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer
- S Ohkawa
- , T Okusaka
- & I Hyodo
-
Translational Therapeutics
| Open AccessStress hormones reduce the efficacy of paclitaxel in triple negative breast cancer through induction of DNA damage
- A Reeder
- , M Attar
- & M S Flint
-
Clinical Study
| Open AccessOptimizing CIGB-300 intralesional delivery in locally advanced cervical cancer
- M R Sarduy
- , I García
- & S E Perea-Rodríguez
-
Clinical Study
| Open AccessA phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer
- T Sakiyama
- , J Tsurutani
- & K Nakagawa
-
Clinical Study
| Open AccessExposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression
- M Zhu
- , R Tang
- & Y Zhang
-
Translational Therapeutics
| Open AccessDual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation without inducing empty basement membrane sleeves in xenograft tumours
- O Coutelle
- , L M Schiffmann
- & U T Hacker
-
Translational Therapeutics
| Open AccessAntagonism between granulocytic maturation and deacetylase inhibitor-induced apoptosis in acute promyelocytic leukaemia cells
- D Hennig
- , S Müller
- & O H Krämer
-
Clinical Study
| Open AccessPemetrexed for previously treated patients with metastatic gastric cancer: a prospective phase II study
- D S Zhang
- , Y Jin
- & R H Xu
-
Clinical Study
| Open AccessPharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer
- L Ansaloni
- , F Coccolini
- & M Zucchetti
-
Clinical Study
| Open AccessCombination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer
- L Bazzola
- , C Foroni
- & D Generali
-
Translational Therapeutics
| Open AccessNew small molecules, ISA27 and SM13, inhibit tumour growth inducing mitochondrial effects of p53
- D Sorriento
- , C Del Giudice
- & G Iaccarino
-
Clinical Study
| Open AccessRelationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma
- A B Suttle
- , H A Ball
- & L Pandite
-
Clinical Study
| Open AccessBosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study
- S J Isakoff
- , D Wang
- & E Calvo
-
Clinical Study
| Open AccessDose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study
- E Van Cutsem
- , C-P Li
- & T Ciuleanu
-
Clinical Study
| Open AccessIntra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study
- J Sehouli
- , A Reinthaller
- & R Chekerov
-
Letter to the Editor
| Open AccessCoexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer
- A Choughule
- , R Sharma
- & A Dutt
-
Translational Therapeutics
| Open AccessInhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells
- C D’Amato
- , R Rosa
- & R Bianco
-
Translational Therapeutics
| Open AccessGemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo
- T E Bapiro
- , K K Frese
- & F M Richards
-
Clinical Study
| Open AccessPhase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies
- A R Tan
- , A Dowlati
- & H A Burris III
-
Translational Therapeutics
| Open AccessOral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation
- J J M A Hendrikx
- , J S Lagas
- & A H Schinkel
-
Clinical Study
| Open AccessA phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
- C-C Lin
- , W-C Su
- & J C-H Yang
-
Clinical Study
| Open AccessPharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours
- N A G Lankheet
- , J S L Kloth
- & N Steeghs
-
Clinical Study
| Open AccessA phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours
- F A L M Eskens
- , P Tresca
- & V Dieras
-
Mini Review
| Open AccessMechanism and consequences of RAF kinase activation by small-molecule inhibitors
- M Holderfield
- , T E Nagel
- & D D Stuart
-
Translational Therapeutics
| Open AccessSe-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models
- S Cao
- , F A Durrani
- & Y M Rustum